We undertook to systematically analyze the entire mitochondrial genome by gene amplification and direct sequencing in ten patients with myelodysplasia; results were compared with concomitantly studied eight normal volunteers as well as mtDNA sequences in accepted databases. Nucleotide changes that were present in our normal controls as well as those in published databases were counted as polymorphisms. Overall, there was no increase in the number of mtDNA genes harboring polymorphisms or "new" mutations between our patients and normal controls, although there were a few more mtDNA changes resulting in amino acid changes in myelodysplasia (9 in 8 controls versus 16 in 10 patients).
Introduction
The myelodysplastic syndromes (MDS) are a heterogenous group of hematologic diseases, characterized by bone marrow failure and an increased risk of malignant transformation 1 .
Cytogenetic abnormalities are highly prevalent and correlate with prognosis and progression to leukemia [2] [3] [4] . The more aggressive categories of MDS, especially disease secondary to exposure to alkylating drugs, topoisomerase inhibitors, and radiation, share risk factors with acute leukemia and show stereotypical chromosome abnormalities [5] [6] [7] . As in other premalignant conditions, genomic instability has been implicated in myelodysplasia. However, as with acute myeloid leukemia, the basis for the genomic instability required to generate the number of genetic lesions of a fully malignant phenotype, has not been explained. In particular, there is little evidence of defects in mismatch repair and spindle checkpoint genes, or for other hypothesized mechanisms 1, 8 . Ras gene mutations are the most frequent molecular abnormalities present in myelodysplasia, followed by p15 gene hypermethylation, FLT3 duplication, and p53 mutation, but these abnormalities are neither uniformly present nor characteristic of the syndromes 9, 10 . One clue to a possible basis for genomic instability in myelodysplasia may be provided by the constitutional disease called Pearson's syndrome, in which sideroblastic anemia accompanies pancreatic abnormalities 11, 12 . In this inherited disorder, a number of deletions of mtDNA, as well as direct repeats, deletion-dimers, deletion-multimers, or duplications were observed 12 . Additionally, genetic changes in mtDNA have been hypothesized more widely to play important roles in senescence, malignancy 13 , and autoimmune disease 14, 15 . In comparison to the nuclear genome, mtDNA shows some modification of the universal genetic code [16] [17] [18] , a paucity of introns, and lack of histone protection. Past evidence has indicated that the mtDNA repair capacity of mitochondria is limited and the proximity of mtDNA to sites of active oxygen species generation is suggestive that mtDNA might be more susceptible to mutation than nuclear DNA. Although
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Based on the observation of sideroblastic anemia in Pearson's syndrome as well as the theoretical concerns described above led to speculation that mtDNA abnormalities might be pathophysiologic in human myelodysplasia. Gatterman and colleagues initially described abnormalities in the cytochrome c oxidase (CO) gene in patients with acquired idiopathic sideroblastic anemia 20 , and later in refractory anemia with excess blasts, lacking ringed Because mtDNA abnormalities might be reflective of an increased susceptibility to mutagenesis in patients with bone marrow failure, as well as provide a link to the development of nuclear genomic instability, cytogenetic abnormalities, and leukemic transformation, we undertook a systematic determination of mtDNA sequence in patients with myelodysplastic syndrome. Our results do not support a role for abnormalities in mtDNA in myelodysplasia, and the minor changes that were found may be explicable as the result of simpler features of the underlying pathophysiology of these diseases or naturally occurring mutations in mtDNA.
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Materials and Methods

Patients and normal controls
Patients with myelodysplastic syndrome (MDS) and controls are described in Table 1 . Blood and bone marrow specimens were collected after informed consent was obtained following protocols approved by the Institutional Review Board of the National Heart, Lung and Blood Institute. MDS was diagnosed by peripheral blood and bone marrow findings according to criteria of the French-American-British classification system 25 .
Mt DNA extraction and amplification
Total DNA extraction. Mononuclear cells from bone marrow and peripheral blood were separated by density gradient centrifugation and washed twice in phosphate buffered saline.
DNA was extracted using QIAamp DNA blood mini kit (Qiagen, Valencia, CA). Extracted DNA was resuspended in TE buffer (pH 7.5) containing 10 mM Tris and 1 mM EDTA.
Oligonucleotide primers. To directly sequence the entire mtDNA, we used 20 primer pairs based on a modification of a published protocol 26 in order to obtain 20 partially overlapping segments ( Table 2 ). The COI and COII genes were amplified using additional 6 and 3 primer pairs respectively for the confirmation of mutations in these regions. The COI gene at mtDNA map position 5,904 to 7,445 was reamplified to produce 6 completely over-lapping polymerase chain reaction (PCR) fragments to examine the reported 'hot spots', using considered a new mutation. New mutations were confirmed by re-amplification of the region using a separate cell specimen for DNA extraction.
Mitochondrial genomic instability (mtGI)
We determined the mtGI using 11 mitochondrial markers: poly ( 
Statistical analysis
The Mann-Whitney test was used to evaluate statistical differences in the numbers of affected mtDNA genes, newly detected mtDNA mutations, and amino acid changes between patients and normal volunteers; P < 0.05 was considered significant.
Results
MtDNA PCR products
The entire 16,569 bp mitochondrial genome was completely amplified using 20 overlapping 809 -1,288 bp PCR products, yielding single distinct bands for all 20 primer sets. These PCR products were then subjected to direct sequencing.
MtDNA nucleotide changes in normal controls and patients
Among hematological normal control subjects, there were 102 mtDNA sequence variants, which consisted of 75 polymorphisms already listed in a published polymorphism database (http://infinity.gen.emory.edu/mitomap.html) and 27 new sequence variations not previously recorded, including unpublished mtDNA polymorphisms (Table 3) . A total of 126 mtDNA nucleotide changes were noted among the 10 patients (Table 4) , 30 nucleotide variants (mean = 3.0) were identified as mutations, and five mutations were predicted to produce amino acid change (Table 5 and Fig. 2 ). The 102 nucleotide changes (mean=12.8) among the 8 normal individuals were distributed throughout the mitochondrial genome, and none of new sequence variants led to amino acid changes (Table 5) .
'Hot spot' mutations
9
Mutations of mtDNA at C7,264A and del A 7,289 (COI gene region), G7,595C and T7,594G (COII gene region) ranging from 15 to 40% have been recently reported in MDS 24 . In the current study, known 8 polymorphisms were detected in the COI and COII gene among our patients (Table 4) .
Statistical comparisons
Compared with the 2001 Revised Cambridge Reference Sequence and with sequences from normal subjects and patients, we excluded nucleotide changes found in both normal controls and patients. Although there was a small increase in the number of amino acid changes predicted to result from polymorphisms and mutations in the MDS group (mean=1.6) compared to healthy individuals (mean=1.1), this difference was not statistically significant (Table 6 ). There was no difference in the number of affected mtDNA genes in patients with MDS and healthy individuals (Table 5) . For mutations alone, only those from patients showed amino acid changes (mean=0.5) ( Table 5) .
we used homopolymeric tracts and deletions reported for the detection of mitochondrial genomic instability in human tumors. Among the 11 markers, abnormalities were observed in three poly (C)s, starting at bp 303, 311 and 16,184, respectively. While there was a statistical significance difference between MDS group (n=18, mean=1.8) and control group (n=8, mean=1.0), too few samples were analyzed to exclude the possibility that the C stretch abnormalities had segregated randomly due to their relative frequency in normal populations (see Discussion).
Discussion
To date, over 100 point mutations and more than 200 deletions and rearrangements in mtDNA have been associated with disease, and new mutations are being described every year 15 . Ironically, the database of "normal" mtDNA sequences is relatively limited. The classic Cambridge Reference Sequence, based on a consensus analysis of a placenta, the HeLa cell line and some information from the bovine sequence, has recently been corrected based on a reanalysis of the original placenta 27 . While other sequences have been reported in the literature and to computerized databases, the origin of the tissues tested has often been from individuals suspected of harboring pathologic mutations or their family members.
Even the distinction between polymorphisms, which are common, and new mutations, is poorly demarcated. For these reasons, in the current study we also undertook to determine the sequence of bone marrow mtDNA from a comparable number of age-matched normal volunteers.
In the current work, we found a large number of polymorphisms as well as apparent new mutations in both patients and controls, with no statistical difference overall between these two populations of individuals. For the myelodysplasia patients, there was a modest number of "new" (not present in http://www.gen.emory.edu/mitomap.html) mutations that resulted in predicted amino acid changes in the gene product; among the ten patients, five mutations producing nonsynonymous alterations were found in NADH dehydrogenase (ND)2, COII, ATPase 6, ND6.and cytochrome b (CYTB). No patient showed more than a single such amino acid change, and the majority of the myelodysplasia patients therefore were not distinguishable from normal individuals. We did not observe small deletions. Large deletions, in particular the common 4.9 kb deletion between the ATPase 8 and ND5 genes 32, 33 and other large deletions that characterize Pearson's syndrome, or deletions observed in some other constitutional mtDNA diseases would need additional experiments to confirm.
Our results differ and in some respects fail to confirm data from other laboratories which have addressed the role of mtDNA in myelodysplasia. Gatterman and colleagues have used temperature gradient gel electrophoresis to identify duplexes of amplified mtDNA products, and then directly sequenced the region implicated 20, 23 . Looking first at acquired idiopathic sideroblastic anemia, due to its similarity to Pearson's syndrome and the obvious mitochondrial involvement, they first reported mutations producing amino acid sequence changes, mainly in the CYTB and COI genes 20, 23 . Subsequently, these investigations were expanded to other myelodysplasia categories and revealed mutations in CYTB in refractory anemia with excess blasts as well as early leukemia. In total, new mutations have been reported in ten sideroblastic anemia cases and seven other myelodysplasias 23 . Comparison of these data with our own is not entirely straightforward, partly because the German investigators did not globally query mtDNA in their cases, the number of negative cases is not described, nor were normal controls included. The putatively pathogenic mutations that they describe are not present in published databases and were not found among our normal controls. However, in the three patients with sideroblastic anemia whom we studied, none showed mutations producing amino acid changes. We cannot exclude that examination of larger numbers or more selected clinical subtypes of sideroblastic anemia patients might not reveal mutational events, but our data do not support a general abnormality in mtDNA sequence in this syndrome. Reddy and colleagues also reported major abnormalities in mtDNA sequence in myelodysplasia, including apparent "hot spots"
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: sixteen of the 20 MDS cases showed mtDNA mutations, four in COI only, three in COII only, and nine in both genes (only portions of these genes were sequenced in this study). The COI changes included deletions, insertions, and substitution mutations; COI mutations were most frequently seen as C7,264A (25%) and del A 7,289 (15%), and COII gene mutations were most frequently seen at T7,594G (30%) and G7,595C (40%). Even more remarkable, all the substitutional mutations led to amino acid changes or generation of a termination codon. These results are in striking contrast to our own limited number of new mutations, of which none were found at the putative " In addition to the few new mutations, we also noted a modest increase in homopolymeric poly (C) tracts; differences in these tracts have been associated with mitochondrial genomic instability analogous to microsatellites in nuclear genomic instability.
Indeed, microsatellite instability has been described in two of 26 patients with myelodysplasia 34 . However, in the mitochondrial forensic community, these regions are referred to as the C-Stretch regions and the most notable occurs when a T at 16189 becomes a C resulting in a C-stretch. Within the population databases, there are a significant number of individuals that have this substitution; for example, the FBI database indicates that about 9.8% of Caucasians and 12.6% of African Americans have this C -stretch (http://www.fbi.gov/hq/lab/fsc/backissu/april2002/miller1.htm). Therefore, since our numbers are small, this is probably not a significant difference (personal communication, Thomas Parsons, AFDIL, AFIP, DOD). Clearly, it is tempting to associate both the limited new mutations seen in a few patients and the abnormal homopolymeric tracts with the pathophysiology of myelodysplasia. However, we believe that a more likely and stringent interpretation is that these apparent abnormalities are secondary to the small numbers of stem cell clones operating to support hematopoiesis in this bone marrow failure syndrome.
Likely both mtDNA mutations (and also, less frequently, nuclear DNA mutations) and differences in homopolymeric length are prevalent among hematopoietic stem and progenitor cells and ordinarily of no physiologic consequences. Analysis of total DNA results in an averaging of these abnormalities, a biologic regression to the normal mean. Such abnormalities will be more likely observed when limited numbers of clones are subjected to Abbreviations: NC, non-coding region including hypervariable segments; M, mean; †, amino acid change; 0, no amino acid change.
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